Company Overview of XDx, Inc.
XDx, Inc. operates as a molecular diagnostics company that discovers, develops, and commercializes noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company focuses on immune-mediated conditions that require life-long monitoring and testing to avoid or to respond to serious complications. It offers AlloMap HTx molecular expression test to monitor heart transplant recipients for acute cellular rejection; AlloMap LTx molecular expression test, a gene expression-based test to monitor cellular rejection in lung transplant recipients; and AlloMap molecular expression testing for non-invasive blood test that aids physicians in determini...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for XDx, Inc.
Chief Executive Officer and President
Vice President of Finance and Commercial Operations
Chief Medical Officer and Executive Vice President
Vice President of Technical Operations and Senior Director of Xdx Reference Laboratory
Compensation as of Fiscal Year 2012.
XDx, Inc. Key Developments
XDx, Inc. Appoints Peter Maag as President and CEO
Oct 1 12
XDx, Inc. announced that Peter Maag, Ph.D., has joined XDx as President and Chief Executive Officer, effective immediately. Dr. Maag has 20 years of global life science experience, leading the development of new diagnostic solutions with a global impact. Prior to joining XDx, Peter was President, Novartis Diagnostics. In this role, Dr. Maag accelerated growth in the company's blood screening business, which screens 80% of the US and 30% of the global blood supply.
XDx, Inc. Presents at The Burrill Personalized Medicine Meeting, Sep-13-2012 10:30 AM
Aug 17 12
XDx, Inc. Presents at The Burrill Personalized Medicine Meeting, Sep-13-2012 10:30 AM. Venue: Bently Reserve, 301 Battery Street, San Francisco, CA 94111, United States. Speakers: Matthew J. Meyer, Chief Business Officer.
XDx, Inc. and Laboratory Corp. of America Holdings Enter into Collaboration and License Agreement to Develop Lupus Flare Predictor Test
May 23 12
XDx, Inc. announced that it has entered into a collaboration and license agreement with Laboratory Corp. of America Holdings whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The agreement combines XDx's autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp's diagnostic development and commercialization resources. Financial terms of the agreement were not disclosed. SLE, also known as lupus, is a chronic autoimmune disease affecting over 1.5 million people in the U.S., according to the Lupus Foundation of America. Lupus disease flares are periods of increased disease activity. The major challenge for physicians managing patients with lupus is to treat this active phase without allowing the treatment itself to cause long-term damage. Treatment for active lupus differs, depending on the organ systems involved and disease severity. Current treatment often includes a combination of drugs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|